drug

I am not sure how to explain a man working all his life to be successful and then, on a whim, flushing it all down the toilet. That is exactly what Ryan Lochte did. Lochte lied to authorities in Rio. He has been formally charged with filing a false robbery report. This is a man who performed brilliantly in the Olympic pool. He was a set up to collect at least tens of thousands of dollars in sponsorships. He has lost almost all of that. Sometimes, it is extremely hard to explain human behavior.

Man, it is hot and I hope that you like hot, because the long-term outlook is for more heat!!

This is just terrible. From WaPo – In this 12th-century town, as many as 70 percent of the homes were vacant in the off-season. There were fewer people on the streets. Numerous teenagers had left for good. And that was before the earthquake. As the search through the ­debris continued and hopes dimmed that rescuers would find more survivors, cities and towns hit hard by Wednesday’s devastating temblor in central Italy began to process the full extent of the disaster. Churches fell. Piazzas were ruined. Neighborhoods were leveled. The body count was at least 250 and set to grow. But in many of those towns, already fighting a long battle against depopulation, a deeper anxiety began to spread.

Yuck!!  EpiPen monopoly – A two-pack of the injectors, which release epinephrine to stop an allergic reaction, has risen from less than $100 in 2007 to $608 today. Mylan said the company never intended for patients to pay the full price, expecting insurers would carry the load. “We recognize the significant burden on patients from continued, rising insurance premiums and being forced increasingly to pay the full list price for medicines at the pharmacy counter,” chief executive Heather Bresch said in a statement. (Oh, and here’s the good part.) The debate is the latest to embroil Congress in the battle over increasing drug costs and their role in escalating health insurance premiums. EpiPen’s rising price is particularly notable because state and federal legislation have been key to the drug’s rapid growth. Annual prescriptions for EpiPen products have more than doubled in the past decade to $3.6 million, according to IMS Health data. Mylan benefited from factors including failed competitors, patent protections and laws requiring allergy medications in schools. Having a virtual monopoly has facilitated the rapid price hike. Mylan reached $1 billion in sales for the second time last year.